# Fruquintinib


Cat. No.:	HY-19912		
CAS No.:	1194506-26	-7	
Molecular Formula:	C <sub>21</sub> H <sub>19</sub> N <sub>3</sub> O	5	
Molecular Weight:	393.39		
Target:	VEGFR		
Pathway:	Protein Tyrosine Kinase/RTK		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	1 year
		-20°C	6 months

## SOLVENT & SOLUBILITY

Preparing Stock Solutions		Solvent Mass Concentration	1 mg	5 mg	10 mg	
		1 mM	2.5420 mL	12.7100 mL	25.4201 mL	
	5 mM	0.5084 mL	2.5420 mL	5.0840 mL		
		10 mM	0.2542 mL	1.2710 mL	2.5420 mL	
	Please refer to the sc	lubility information to select the app	propriate solvent.			
ı Vivo		one by one: 10% DMSO >> 40% PEC ng/mL (1.50 mM); Clear solution	G300 >> 5% Tween-8	0 >> 45% saline		
		2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 0.59 mg/mL (1.50 mM); Clear solution				
		3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 0.59 mg/mL (1.50 mM); Clear solution				

BIOLOGICAL ACTIV	YITY		
Description	Fruquintinib (HMPL-013) is a	nighly potent and selective VEG	FR 1/2/3 inhibitor with IC $_{50}$ s of 33, 0.35, and 35 nM, respectively.
IC <sub>50</sub> & Target	VEGFR1 33 nM (IC <sub>50</sub> )	VEGFR2 35 nM (IC <sub>50</sub> )	VEGFR3 0.5 nM (IC <sub>50</sub> )
In Vitro		'	ndent KDR phosphorylation in HEK293-KDR cells and VEGF-A nM and 1.7 nM, respectively. Similarly, potent VEGFR3

# Product Data Sheet



	attenuation by fruquintinib is observed in primary HLECs, with IC <sub>50</sub> s of 1.5 nM and 4.2 nM for VEGF-C stimulated VEGFR3 phosphorylation and proliferation, respectively. Fruquintinib suppresses the tube branching, tube length and area in a concentration-dependent manner. The tubule length of primary HUVECs decreased by 74% and 94% at 0.03 and 0.3 μM of fruquintinib, respectively. Fruquintinib inhibits HUVEC tubule growth and CAM angiogenesis. Tube formation is suppressed significantly after treatment with fruquintinib at 0.3 μM for 18 hours <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Gastric cancer BGC-823 model is found to be most sensitive to fruquintinib. In this model, fruquintinib inhibits tumor growth by 62.3% and 95.4⊠98.6%, at 0.5 and 2 mg/kg once daily dosing, respectively. When the dose is elevated to 5 mg/kg and 20 mg/kg, the tumors regress by 24.1% and 48.6%, respectively. The level of anti-tumor growth activity of fruquintinib varies in different tumor xenograft models. Fruquintinib significantly decreases the micro-vessel density even at the lowest dose of 0.8 mg/kg <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL	
TROTOCOL	
Cell Assay <sup>[1]</sup>	Primary HUVECs or HLECs in exponential phase are suspended in 100 μL of RPMI-1640 media containing 0.5% FBS, and seeded at 5000 cell/well in 96-well plates pre-coated with 0.2% gelatin or fibronectin, and incubated overnight in a 5% CO <sub>2</sub> , 37°C incubator. Fruquintinib and VEGF-A165 or VEGF-C (50 ng/mL) are added and incubated for 48 hours. Viability of the cells is determined using CCK-8 assay format <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration <sup>[1]</sup>	Mice: The patient derived xenograft models are established after the primary tumor adopted serial passages in vivo. Once tumors have grown to 100-300 mm <sup>3</sup> , the animals are randomly assigned with 6-8 animals per group. The mice are treated orally with the vehicle (control group) or fruquintinib at a dose range of 0.5-20 mg/kg suspended in the vehicle (treated group) once daily for 3 weeks. In combination studies, docetaxel (Taxotere, 5 mg/kg) or oxaliplatin (10 mg/kg) is administered to nude mouse via intravenous injection, once a week. Tumor size and body weights are measured 3 times a week. Tumor volumes (TV) are calculated <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- Mol Syst Biol. 2023 Dec 18.
- Eur J Med Chem. 2023 Nov 5, 259, 115703.
- Chemotherapy. 2023 Jan 9.
- Biochem Biophys Res Commun. 2023 Apr 10.
- Cell Reprogram. 2021 Jun 2.

See more customer validations on  $\underline{www.MedChemExpress.com}$ 

#### REFERENCES

[1]. Sun Q, et al. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45.

#### Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA